Active substanceDextran + Inosine + Potassium chloride + Calcium gluconate + Lidocaine + Magnesium sulfate + Sodium bicarbonate + Sodium chlorideDextran + Inosine + Potassium chloride + Calcium gluconate + Lidocaine + Magnesium sulfate + Sodiumbicarbonate + Sodium chloride
Similar drugsTo uncover
  • Console®
    solution
    SAMSON-MED, LLC     Russia
  • Dosage form: & nbspintracoronary solution
    Composition:

    1000 ml of solution contains:

    Active substances:

    Potassium chloride - 1.19 g.

    Calcium gluconate - 0.51 g.

    Magnesium sulfate heptahydrate - 3.94 g.

    Sodium bicarbonate - 0.84 g.

    Lidocaine hydrochloride is 0.27 g.

    Inosine - 0.268 g.

    Polyglukin, a solution for infusions of 6% (6% solution of a polymer of glucose-dextran with a molecular weight of 50,000 to 70,000 in a 0.9% solution of sodium chloride) - up to 1000 ml.

    Osmolality from 350 to 400 mmol per 1 kg of water.

    Description:Transparent, colorless or slightly yellowish liquid, odorless.
    Pharmacotherapeutic group:Cardioplegics
    ATX: & nbsp

    B.05.X.A   Electrolyte solutions

    Pharmacodynamics:

    Perfusion of the heart with the polyionic buffered solution Console® causes the cessation of mechanical and electrical activity of the heart and prevents damage to cells from total ischemia and subsequent reperfusion during restoration of cardiac blood flow. The polyglucin, which is part of the solution, with its ability to bind water and improve microcirculation, prevents sharp swelling of the mitochondria and intracellular edema.Used concentrations of cardioplegic agents cause reversible stabilization of excitable membranes of cardiomyocytes and other cells, which does not lead to their irreversible damage as a result of prolonged total ischemia and subsequent organ reperfusion during surgery.

    Pharmacokinetics:Studies have not been conducted.
    Indications:Used for cardioplegia in operations that require stopping heartbut in conditions of artificial circulation.
    Contraindications:Hypersensitivity to any of the components of the solution.
    Dosing and Administration:Applied for cardioplegia.

    For cold cardiac arrest, Consol® with a temperature of + 4 ° C is used. The initial volume is perfused in an amount of 400-600 ml with simultaneous intrapericardial cooling and then every 30-40 minutes - 200-400 ml of Consol® solution (at a temperature of + 4 ° C), depending on the size of the heart.

    With antegrade delivery through the root of the aorta, the solution is perfused at a pressure of 60-80 mmHg. With selective cardioplegia, Consol® is infused into the coronary arteries at a pressure of 50-70 mmHg, the retrograde delivery method is 40-50 mmHg.Intrapericardial cooling in all cases is necessary and it is carried out with saline solution of sodium chloride (in the form of an ice gruel).

    Side effects:Not found.
    Form release / dosage:
    Solution for intracoronary perfusion.
    Packaging:

    400 ml in glass bottles with a capacity of 500 ml, sealed with rubber medical plugs, crimped caps made of aluminum and polypropylene.

    For each bottle stick the label self-adhesive.

    One bottle together with instructions for medical use in a pack of cardboard box.

    For 15 vials, together with instructions for medical use in quantities corresponding to the number of bottles, in boxes of corrugated cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after the date shown on the package.

    Terms of leave from pharmacies:For hospitals
    Registration number:LSR-009914/08
    Date of registration:11.12.2008
    The owner of the registration certificate:SAMSON-MED, LLC SAMSON-MED, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp16.01.2018
    Illustrated instructions
      Instructions
      Up